Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + Cytarabine in Pediatric Relapsed/Refractory AML
NCT01853228Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), sponsored by Janssen Pharmaceutical. Started Oct 2013; status: terminated.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01853228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853228.